Kornimate/medical-research-clean huggingface dataset:
clinical improvement obtained by endoscopic ilio-psoas tenotomy (lesser trochanter versus acetabular notch)

Conditions: Tendinopathy

Summary: the purpose of the study is to assess oxford hip score at baseline, at 2 months and at over 12 months.

this is an interventional, comparative, randomized study, in 2 parallel groups, single-blind (the patient does not know which technique he will benefit from, the surgeon will carry out the surgery and will therefore be informed of the result of the randomization ) and monocentric. comparative prospective cohort study of an endoscopic tenotomy surgery of the iliopsoas tendon at the level of the lesser trochanter versus at the level of the acetabular notch, in the context of anterior pain for impingement between the iliopsoas tendon and the prosthetic cup in patients after total hip prosthesis. the study will be proposed to the patient during the preoperative consultation. patients eligible for surgery will be offered the study. after a reflection period of at least 15 days, patients who agree to participate in the study will be included. randomization will be done by drawing lots to decide whether the endoscopic tenotomy will be performed at the level of the lesser trochanter or at the level of the acetabular notch. the surgery will be performed under general anesthesia with standardized multimodal analgesia. whatever the techniques, the approaches, the instruments to perform the procedure and the postoperative course will be identical, as in usual practice.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years old; * definite diagnosis of iliopsoas tendinopathy due to conflict between the tendon and the prosthetic cup; * failure of first-line conservative treatment; * planned endoscopic tenotomy; * affiliation to the social security scheme; * signed informed consent. exclusion criteria: * revision total hip prosthesis, multiple operations prior to tenotomy; * other surgical or medical interventions planned during the study; * participation in another clinical trial, or during a period of exclusion from another clinical trial; * pregnant or likely to be pregnant (of childbearing age, without effective contraception) or breastfeeding; * patient deprived of liberty or under guardianship or curatorship or unable to give consent.
a study of pf-06647020 for adult patients with advanced solid tumors

Conditions: Neoplasms

Summary: to assess the safety and tolerability at increasing dose levels of pf-06647020 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended phase 2 dose.


Eligibility criteria:
q2w inclusion criteria: * diagnosis of platinum resistant or refractory ovca having received 2 or fewer prior lines, or recurrent advanced nsclc having received 3 or fewer prior lines * performance status of 0, 1, or 2 * adequate bone marrow, kidney, and liver function q2w exclusion criteria: * ovca pts excluded with any of the following: non-epithelial, including malignant mixed mullerian tumors, unresolved bowel obstruction * brain metastases requiring steroids * major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of study treatment start * active and clinically significant bacterial, fungal, or viral infection q3w inclusion criteria: * diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy or for whom no standard therapy is available * performance status of 0 or 1 * adequate bone marrow, kidney, and liver function * part 2 includes ovarian cancer, target expressing triple negative breast cancer and non small cell lung cancer patients q3w exclusion criteria: * ovca pts excluded with any of the following: non-epithelial, including malignant mixed mullerian tumors, prior radiotherapy to pelvis/abdomen, pts with ca-125 only disease, unresolved bowel obstruction * brain metastases requiring steroids * major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of study treatment start * active and clinically significant bacterial, fungal, or viral infection

Keywords: adc pf-06647020 solid tumors tumors neoplasm metastasis tnbc triple negative breast cancer nsclc non small cell lung cancer advanced metastatic breast cancer ovarian cancer ovca
clinical study of jianfei kangfu cao in the treatment of pss-ild

Conditions: Primary Sjogren's Syndrome; Interstitial Lung Disease

Summary: this study will evaluate the safety and efficacy of jianfei kangfu cao in the treatment of primary sjogren's syndrome associated interstitial lung disease.

this study will be a randomized, double-blind, positive control clinical trial with a course of 24 weeks. 1. random scheme:the das for interactive web response system(iwrs) will be used to calculate and distribute random numbers and dispensing drugs. 2. blind method ：the test process will be in a double-blind state. 3. control drug: the lung rehabilitation training will be used as control in this trial.

Eligibility criteria:
inclusion criteria: 1. according to the 2012 acr classification of primary sjogren's syndrome . 2. ct confirmed interstitial lung disease; 3. dlco≧40%; 4. stable treatment for at least 12 weeks; 5. patients with good compliance should sign informed consent before the tria. exclusion criteria: 1. the patient is using or has used anti pulmonary fibrosis drugs; 2. pulmonary infection, tumor and other connective tissue diseases; 3. chronic obstructive pulmonary disease, bronchial asthma and tuberculosis; 4. patients with severe hypertension, diabetes and heart, liver and renal failure; 5. women with reproductive needs; 6. idiopathic pulmonary interstitial disease; 7. the researcher thinks that it is not suitable to participate in this experiment; 8. participants in other clinical trials.

Keywords: safety efficacy primary sjogren's syndrome interstitial lung disease
clinical evaluation of the cadencetm system in detection of coronary artery diseases

Conditions: Coronary Artery Disease

Summary: the purpose of the study is to evaluate the effectiveness of the cadence system, a non-invasive device, in detecting greater than or equal to 50% coronary stenosis anywhere in the coronary tree.


Eligibility criteria:
inclusion criteria: * over 18 years old * willing and able to give informed consent * indicated for angiography evaluation. exclusion criteria: * pregnant or nursing * presence of pacemaker/defibrillator * presence of artificial valve * presence of severe valve disease * presence of congenital heart defect * left ventricular assist device (lvad) * presence of a bypass graft * presence of scars on the site thorax areas * coarctation of the aorta * participation in trial within 30 days prior to collecting cadencetm data * asthma with wheezing * inability to lie flat in the supine position * acute stemi * heart transplant * recent cocaine use
the improvements of dietary supplement of black rice on metabolic syndrome

Conditions: Metabolic Syndrome X

Summary: the purpose of this study is to thoroughly investigate how the interaction between black rice and human gut microbiota affects metabolic diseases, this study will recruit patients with metabolic syndrome (ms) and provide them with dietary supplementation of black rice (50 g/day) for 3 months to observe its effect on the development of ms. the focuses of this project are to elucidate how black rice consumption affects the composition and metabolism of intestinal bacteria as well as the development of ms, and to further analyze whether the changes in intestinal bacteria are associated with the changes in ms improvements.


Eligibility criteria:
inclusion criteria: * individuals meeting at least 3 of the following 5 criteria will be chosen: * abdominal obesity: using the waist standard for asians: waist≥90 for male and ≥80 for female * high blood sugar: fasting plasma glucose≥5.6mmol/l (100mg/d l) or individuals diagnosed with diabetes and being treated * hypertension: systolic blood pressure≥130 mm hg or diastolic blood pressure≥85 mm hg or individuals diagnosed with hypertension and being treated * dyslipidemia: fasting total triglycerides≥1.70 mmol/l(150 mg/d l) or individuals undergoing lipid-lowering therapy * fasting plasma high-density lipoprotein cholesterol\<1.03mmol/l (40mg/dl) for male or \<1.3mmol/l (50mg/dl) for female. exclusion criteria: * having current or former cardiovascular disease, including coronary heart disease (e.g., angina pectoris, myocardial infarction, coronary revascularization, abnormal q waves in ecg), stroke (e.g., congestive, hemorrhagic, or transient ischemic stroke), and intermittent claudication caused by peripheral arterial diseases; * severe clinical conditions that may compromise patients' participation in experiments, e.g., digestive diseases leading to inability to maintain black rice uptake, patients receiving parenteral nutrition supply, malignancies in progress, and mental illness; * immunodeficiency disease or aids, chronic inflammation conditions * drug abuse or alcoholism (\>80g/d).

Keywords: metabolic syndrome black rice
characterize patients with moderately active rheumatoid arthritis (ra)

Conditions: Rheumatoid Arthritis

Summary: 1. to assess the baseline (i.e. ra therapy initiation) characteristics in a real-world setting across two moderate ra cohorts: a test group of patients newly exposed to etanercept (enbrel) therapy and a control group of patients with similar disease characteristics newly exposed to other, non-biologic therapies. 2. to assess the change over time (from baseline to the most recent follow-up) in the characteristics described at baseline in 2 british society for rheumatology biologics register (bsrbr) cohorts (i.e. moderate ra patients treated with disease modifying anti-rheumatic drugs (dmards) alone versus moderate ra patients treated with enbrel).

retrospective database analysis

Eligibility criteria:
inclusion criteria: the test group will be patients with rheumatoid arthritis, newly starting therapy with etanercept (enbrel). inclusion criteria for the exposed cohort subjects are: * patients aged 18 years and over at the time of diagnosis; * patients from the bsrbr with moderate ra as defined by a das28 (\>3.2 and ≤5.1); * patients who have given informed consent for long term follow-up and access to all medical records; * patients initiating (i.e. at leats one treatment) treatment with etanercept (enbrel) for ra. the control group: * patients aged 18 years and over a the time of diagnosis; * patients from the bsrbr with moderate ra as defined by a das28 (\>3.2 and ≤5.1); * patients who have given informed consent for long term follow-up and access to all medical records; patients are receiving at least one traditional dmard and have never been prescribed a biologic agent; exclusion criteria: per bsrbr registry since data is retropsectively being analyzed
telephone intervention to increase safety in abused women

Conditions: Intimate Partner Violence

Summary: although abuse by an intimate partner is very common and has serious negative effects on women's health, few studies have been done to test ways to increase safety for women in abusive relationships. this study will test a telephone intervention for women who report physical, emotional, and/or sexual abuse within the past 12 months, to see if * women use more safety behaviors and access more community resources * chronic pain, fatigue, depressive, and post-traumatic stress disorder (ptsd) symptoms affect a women's ability to use safety behaviors and access community resources.

women who experience intimate partner violence (ipv) are at increased risk for serious long term negative health sequelae, injury, and death. compared to non-abused women, intimately abused women suffer significantly greater prevalence of depression and post-traumatic stress disorder (ptsd), as well as a host of nonspecific physical symptoms including chronic pain and fatigue (campbell, 2002; golding, 1999; asmundson, coons, taylor, \& katz, 2002; ehlert, gaab, \& heinrichs, 2001; green, baker, sato, washington, \& smith, 2003; woods, 2004). these increased negative health problems contribute to a greater prevalence of ipv among primary care patients, with current (past year) ipv rates of 15 - 28%, compared to 1.5% to 3% in epidemiologic surveys (bauer, rodruguez, perez-stable, 2000; coker, et al., 2000; collins, et al.,1998; kramer, lorenzon, mueller, 2004; richardson, et al., 2002; tjaden \& thoennes, 2000). in spite of this high prevalence and serious negative health sequelae, a recent review of interventions for ipv concluded that there is a serious lack of evidence-based approaches in the primary care setting. no studies were identified that examined the effect of physical and mental health symptoms on the ability to access resources or to increase safety promoting behaviors. this intervention pilot study will speak to this gap in the research. utilizing a randomized controlled clinical trial design, we will follow women who screen positive for current (past year) ipv at a primary care clinic in baltimore, md. women in the control group will receive usual care consisting of a list of community resources for ipv. women in the a nurse-managed/community health worker intervention group will receive usual care augmented by an individualized counseling session followed by a series of 6 telephone calls over 10 weeks. a woman's stage of readiness for change as well as symptoms of pain, fatigue, depression, and ptsd will be evaluated as barriers to resource access and safety behavior initiation.

Eligibility criteria:
inclusion criteria: * female * 18 years of age or older * speaks english * reports physical, emotional, and/or sexual abuse by an intimate partner within past 12 months exclusion criteria: * non-english speaking * currently pregnant

Keywords: intimate partner violence depression ptsd fatigue
safety study of bms-770767 in subjects with type 2 diabetes

Conditions: Diabetes Type 2

Summary: the purpose of this study is to determine if bms-770767 is safe, well tolerated, measure its levels in the blood (pharmacokinetics), and measure the levels of chemicals (biomarkers) that may be affected by this drug (pharmacodynamics) in a type 2 diabetes patient population


Eligibility criteria:
inclusion criteria: * diagnosed with type 2 diabetes with inadequate glycemic control and treated with either diet and exercise alone, or with stable doses (≥ 1500mg/d) of metformin for at least 8 weeks prior to screening * hba1c ≥ 7.0% and ≤ 10.0% with fpg ≤ 240mg/dl (13.3 mmol/dl) exclusion criteria: * women of childbearing potential * history of diabetic ketoacidosis or hyperosmolar nonketotic coma * significant cardiovascular history * history of unstable or rapidly progressing renal disease * impaired renal function defined by a serum creatinine \> 1.4mg/dl (124 µmol/l) for women and \>1.5mg/dl (133 µmol/l) for men * active liver disease and /or significant abnormal liver function defined as ast \> 3x uln and/or alt \> 3xuln and /or serum total bilirubin \> 2.0mg/dl
breaking down barriers to diabetes self-care

Conditions: Type 1 Diabetes; Type 2 Diabetes

Summary: performance of self-care recommendations is key to the successful treatment of diabetes. however, many patients have difficulty adhering to diabetes self-care recommendations. recent results from our own studies and others have identified specific barriers to diabetes self-care. to evaluate the efficacy of a diabetes educator-led group intervention, the breaking down barriers program, that addresses barriers and therefore leads to improved adherence to diabetes self-care recommendations, we will randomize 222 (111 type 1 and 111 type 2) diabetes patients to one of three conditions: 1) the breaking down barriers program, 2) a cholesterol attention control condition, or 3) a 'usual care' control condition. we hypothesize that those assigned to the breaking down barriers group will improve self-care behaviors and glycemic control more than those in the two control groups. we will follow study subjects for one year to determine whether their self-care behaviors and glycemic control improved and if the improvement was maintained over time.


Eligibility criteria:
inclusion criteria: for patients with type 1 diabetes * aged 18-65 * presence of type 1 diabetes mellitus. * 2-25 year duration. for patients with type 2 diabetes * aged 25-65 years * presence of type 2 diabetes mellitus. * 2 years since initial diagnosis. exclusion criteria: * renal disease, microalbumin \>300 ug/mg) * severe peripheral diabetic neuropathy and/or severe peripheral vascular disease * symptomatic severe autonomic neuropathy who may be at risk when increasing activity levels. * women who are currently pregnant * proliferative diabetic retinopathy based on dilated eye examination within one year of study entry. patients whose eye disease is successfully treated will be included. * hba1c levels less than 7.0% (normal range 4.0 - 6.0%). * hba1c levels greater than 14.0% * patients who underwent intensive insulin treatment within one year * a history of severe, unstable myocardial infarction, congestive heart failure or other severe cardiac disease, severe hypertension (systolic more than 160 mmhg or diastolic 90 mmhg) who may be at risk when mildly increasing physical activity * a dsmiv diagnosis of eating disorders including anorexia nervosa, bulimia, and severe weight-related insulin omission. * patients with recent diagnosis (past 6 months) of bipolar disorder, schizophrenia, mental retardation, organic mental disorder, and alcohol or drug abuse * patients whose diabetes diagnosed cannot be clearly classified as type 1 or type 2.

Keywords: adherence self-care behavioral intervention diabetes
a study of mhaa4549a as monotherapy for acute uncomplicated seasonal influenza a in otherwise healthy adults

Conditions: Influenza A

Summary: this is a phase 2, randomized, double-blind, placebo-controlled single dose study in otherwise healthy adults with acute uncomplicated seasonal influenza a to assess the safety and tolerability, efficacy, and pharmacokinetics of mhaa4549a.


Eligibility criteria:
inclusion criteria: * otherwise healthy participants * positive test for influenza a infection * no more than 72 hours elapsed between onset of influenza-like illness and start of study drug * presence of at least one moderate or severe constitutional symptom such as headache, myalgia, fever, chills, fatigue, anorexia, or nausea plus one moderate or severe respiratory symptom such as cough, sore throat, or rhinorrhea * for women of childbearing potential: negative pregnancy test and agreement to use acceptable contraceptive methods for at least 120 days after study drug administration * for men: agreement to use acceptable contraceptive methods for at least 30 days after study drug administration exclusion criteria: * creatinine clearance less than or equal to (\</=) 80 milliliters per minute (ml/min) * any significant medical conditions or laboratory abnormalities * clinical signs and symptoms consistent with otitis, bronchitis, sinusitis, or pneumonia or active bacterial infection * use of antiviral therapy in the period from onset of influenza-like illness and prior to enrollment * pregnancy at screening or is currently pregnant or breastfeeding * investigational therapy within 30 days or 5 half-lives prior to start of study drug, whichever is greater * prior anti-influenza monoclonal antibody use * receipt of a nasal influenza a vaccine within 14 days prior to screening * positive test for influenza b or influenza a+b within 2 weeks prior to study drug * history of significant tobacco use or drug/alcohol abuse * chronic use of oral or inhaled corticosteroids within 30 days prior to screening * autoimmune disease, known immunodeficiency of any cause, or use of immunosuppressive medications * history of any chronic respiratory condition * human immunodeficiency virus (hiv) with cluster of differentiation (cd) 4 count \</= 200 cells per milliliter (cells/ml) in the past 12 months * serious infection requiring oral or iv antibiotics within 14 days prior to screening
efficacy and stability of dexmedetomidine sedation compared to propofol sedation in the drug induced sleep endoscopy

Conditions: Obstructive Sleep Apnea

Summary: obstructive sleep apnea syndrome affect up 12% in adult population. it is associated with an increase rate of hypertension, metabolic syndrome, depression and adverse cardiovascular events. the evaluation of upper airway obstruction is vital to obtain site-specific treatment. drug induced sleep endoscopy (dise) is a routinely exam which allows the direct observation of the upper airway during sedative induced sleep. propofol and dexmedetomidine are sedatives approved for all diagnostic examinations that required sedation.

obstructive sleep apnea syndrome affect up 12% in adult population. it is associated with an increase rate of hypertension, metabolic syndrome, depression and adverse cardiovascular events. the evaluation of upper airway obstruction is vital to obtain site-specific treatment. drug induced sleep endoscopy is a routinely exam which allows the direct observation of the upper airway during sedative induced sleep. propofol and dexmedetomidine are sedatives approved for all diagnostic examinations that required sedation. it's a randomized controlled study. 28 participants will be enrolled and randomized in two groups: in the first group the sedation state will be performed with propofol, while in the second group will be used dexmedetomidine for allow sedation state. the study will be evaluate the different hemodynamic and respiratory changes during sedation in these two different groups and differences in obstructive endoscopic anatomical patterns. this will be the first study in whic dexmedetomidine and propofol will be compared according to european dise recommendation published in august 2018 (references)

Eligibility criteria:
inclusion criteria: * apnea-hypopnea index (ahi) of 15-30. * men and women, age 18-65 years, body mass index (bmi) \< 35 kg/m2, * awake oxygen saturation \> 95% * able to read and sign the consent form exclusion criteria: * chronic obstructive pulmonary disease (copd) * liver disease (child pugh 1-3) * history of chronic use of sedatives, narcotics, alcohol or illicit drugs, * history of 1st and 2nd degree heart block (not paced), * left ventricular ejection fraction (lvef) \< 50%, * allergy to propofol or dexmedetomidine, * oshas (obstructive sleep apnea/hypopnea syndrome) surgical failure patients * pregnant women.

Keywords: drug-induced sleep endoscopy dexmedetomidine airway collapsibility propofol
a study comparing cardiovascular effects of ticagrelor and clopidogrel in patients with peripheral artery disease

Conditions: Peripheral Artery Disease

Summary: the purpose of this study is to compare the effects of ticagrelor and clopidogrel in patients with peripheral artery disease.

a randomized, double-blind, parallel group, multicentre phase iiib study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischemic stroke in patients with established peripheral artery disease (euclid examining use of ticagrelor in pad)

Eligibility criteria:
inclusion criteria: * male and female patients 50 years old or older symptomatic peripheral artery disease exclusion criteria: * patients needing dual anti-platlet drug treatment before start of study planned revascularisation or amputation * patients with known bleeding disorders * patients with a history of intracranial bleed * patients considered to be at risk of bradycardic events unless already treated with a permanent pacemaker

Keywords: peripheral artery disease atherothrombotic events atherosclerosis